737 related articles for article (PubMed ID: 19490092)
1. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Price DA; Martinez AA; Seillier A; Koek W; Acosta Y; Fernandez E; Strong R; Lutz B; Marsicano G; Roberts JL; Giuffrida A
Eur J Neurosci; 2009 Jun; 29(11):2177-86. PubMed ID: 19490092
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation.
Chung YC; Bok E; Huh SH; Park JY; Yoon SH; Kim SR; Kim YS; Maeng S; Park SH; Jin BK
J Immunol; 2011 Dec; 187(12):6508-17. PubMed ID: 22079984
[TBL] [Abstract][Full Text] [Related]
3. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
[TBL] [Abstract][Full Text] [Related]
4. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
5. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
6. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
Kawasaki T; Ishihara K; Ago Y; Baba A; Matsuda T
J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058
[TBL] [Abstract][Full Text] [Related]
7. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
García-Arencibia M; González S; de Lago E; Ramos JA; Mechoulam R; Fernández-Ruiz J
Brain Res; 2007 Feb; 1134(1):162-70. PubMed ID: 17196181
[TBL] [Abstract][Full Text] [Related]
9. CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease.
Chung YC; Shin WH; Baek JY; Cho EJ; Baik HH; Kim SR; Won SY; Jin BK
Exp Mol Med; 2016 Jan; 48(1):e205. PubMed ID: 27534533
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson's Disease.
Pariyar R; Bastola T; Lee DH; Seo J
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216503
[TBL] [Abstract][Full Text] [Related]
11. Cinnamic Acid Protects the Nigrostriatum in a Mouse Model of Parkinson's Disease via Peroxisome Proliferator-Activated Receptorα.
Prorok T; Jana M; Patel D; Pahan K
Neurochem Res; 2019 Apr; 44(4):751-762. PubMed ID: 30612307
[TBL] [Abstract][Full Text] [Related]
12. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
Li C; Biswas S; Li X; Dutta AK; Le W
J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619
[TBL] [Abstract][Full Text] [Related]
13. URB597 and the Cannabinoid WIN55,212-2 Reduce Behavioral and Neurochemical Deficits Induced by MPTP in Mice: Possible Role of Redox Modulation and NMDA Receptors.
Escamilla-Ramírez A; García E; Palencia-Hernández G; Colín-González AL; Galván-Arzate S; Túnez I; Sotelo J; Santamaría A
Neurotox Res; 2017 May; 31(4):532-544. PubMed ID: 28092019
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease.
Esposito E; Impellizzeri D; Mazzon E; Paterniti I; Cuzzocrea S
PLoS One; 2012; 7(8):e41880. PubMed ID: 22912680
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
Moon M; Kim HG; Hwang L; Seo JH; Kim S; Hwang S; Kim S; Lee D; Chung H; Oh MS; Lee KT; Park S
Neurotox Res; 2009 May; 15(4):332-47. PubMed ID: 19384567
[TBL] [Abstract][Full Text] [Related]
16. Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson's Disease.
Wi R; Chung YC; Jin BK
J Immunol Res; 2020; 2020():5093493. PubMed ID: 33062722
[TBL] [Abstract][Full Text] [Related]
17. Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons.
Hong J; Sha S; Zhou L; Wang C; Yin J; Chen L
Cell Death Dis; 2015 Jul; 6(7):e1832. PubMed ID: 26203861
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the D2 receptor regulation and neurotoxicant susceptibility of nigrostriatal dopamine neurons in wild-type and CB1/CB2 receptor knockout mice.
Simkins TJ; Janis KL; McClure AK; Behrouz B; Pappas SS; Lehner A; Kaminski NE; Goudreau JL; Lookingland KJ; Kaplan BL
J Neuroimmune Pharmacol; 2012 Sep; 7(3):533-8. PubMed ID: 22639229
[TBL] [Abstract][Full Text] [Related]
19. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
20. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation.
Chung YC; Kim SR; Park JY; Chung ES; Park KW; Won SY; Bok E; Jin M; Park ES; Yoon SH; Ko HW; Kim YS; Jin BK
Neuropharmacology; 2011 May; 60(6):963-74. PubMed ID: 21288472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
